Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment
Sarcoma
DRUG: TIL|DRUG: Interleukin-2|DRUG: Fludarabine|DRUG: Cyclophosphamide
Number of Participants Who Experienced Serious Adverse Events and Adverse Events, Participants able to safely tolerate preparatory lymphodepletion, infusion of tumor-infiltrating lymphocytes (TIL) and subsequent IL-2, as measured by adverse events and serious adverse events., Baseline to 12 months
Number of Participants With Objective Antitumor Response, Number of participants with objective response (Complete Response (CR) + Progressive Response (PR)) rate at 12 weeks following TIL infusion, as measured by RECIST v1.1, At 12 weeks|Number of Participants With Circulating Tumor-infiltrating Lymphocytes (TIL) Product at 6 Weeks, Number of participants with persistence of TIL infusion product at 6 weeks following treatment, as measured by T-cell receptor repertoire comparison between the infusion product and circulating Peripheral blood mononuclear cell (PBMC)., At 6 weeks
This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment